Sequenom Laboratories Announces National Coverage Agreement With UnitedHealthcare Insurance Company For Prenatal Diagnostic Testing Services

SAN DIEGO, Sept. 17, 2015 Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced today that it has signed a national agreement with UnitedHealthcare Insurance Company, effective October 1, 2015, covering 43 million people throughout the United States, to provide the MaterniT21® PLUS, HerediT® CF Carrier Screen and HerediT® UNIVERSAL Carrier Screen laboratory-developed tests (LDT). The addition of this contract brings the number of covered lives under agreement by Sequenom Laboratories' diagnostic services to more than 200 million.

The MaterniT21 PLUS test reports on trisomy 21, 18, 13, 16 and 22, sex chromosome aneuploidies, fetal sex and select microdeletions in single or multifetal gestations as early as 10 weeks in a pregnancy. Estimates suggest there are about 750,000 pregnancies at high risk for fetal chromosomal abnormalities each year in the United States.

The HerediT CF Carrier Screening test analyzes the most clinically relevant mutations and variants related to cystic fibrosis. The HerediT UNIVERSAL Carrier Screening test is a comprehensive, customizable expanded test that screens for > 250 diseases and > 2,000 disease-causing mutations.

These tests are available exclusively through Sequenom Laboratories as testing services provided to health care professionals. To learn more about these tests, please visit www.laboratories.sequenom.com.

About Sequenom 

Sequenom, Inc. (SQNM) is committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information. To learn how Sequenom is interpreting the genome to improve your life, visit www.sequenom.com.

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT® CF, HerediT® UNIVERSAL, VisibiliT, MaterniT21® PLUS, MaterniT GENOME, and NextView, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists.  Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit www.laboratories.sequenom.com and follow @SequenomLabs.

SEQUENOM®, Sequenom Laboratories™, HerediT® CF, HerediT® UNIVERSAL, VisibiliT™, MaterniT21® PLUS, MaterniT™ GENOME, and NextView™ are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the development of innovative products and services. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.